3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Neoplasm Metastasis
2
Esophageal Neoplasms
2
Stomach Neoplasms
1
Patients With Advanced or Metastatic Solid Tumors
1
Pancreatic Neoplasms
1
Neoplasms, Unknown Primary
1
Hand-Foot Syndrome
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Bile Duct Neoplasms
1
Adenocarcinoma Of Esophagus
1
Adenocarcinoma
1
Interventions
Gemcitabine
27
Fluorouracil
25
Oxaliplatin
21
Cisplatin
19
Leucovorin
17
Bevacizumab
15
130-nm albumin-bound paclitaxel
13
Docetaxel
12
Capecitabine
12
Albumin-Bound Paclitaxel
12
Paclitaxel
11
Irinotecan
10
Carboplatin
9
pembrolizumab
7
Radiotherapy
6
Pemetrexed
6
Nivolumab
6
Erlotinib Hydrochloride
6
Cyclophosphamide
6
Trastuzumab
5
Ramucirumab
5
Ipilimumab
4
Everolimus
4
Crizotinib
4
Cetuximab
4
vandetanib
3
trastuzumab deruxtecan
3
sargramostim
3
folfirinox
3
Sorafenib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Adenocarcinoma
×
tegafur-gimeracil-oteracil
×
Clear all
NCT02564367
2021-04-29
S-1 adjuvant
AIO-Studien-gGmbH
Phase 1/2
Completed
30 enrolled